Improving the safety of immunotherapy

Area of Science:

• Allergy and Immunology
• Clinical Medicine
• Pharmacology

Background:

• Subcutaneous immunotherapy (SCIT) is a common treatment for allergic diseases.
• Systemic reactions (SRs) can occur during SCIT, necessitating careful management decisions.
• Assessing individual risk factors is crucial for patient safety during SCIT.

Observation:

• A case study of a 42-year-old woman experiencing an SR after SCIT highlights the need for personalized management.
• Key risk factors for SRs include asthma control, medications, pollen season, reaction severity, and administration errors.
• Evidence-based risk-mitigation strategies are essential for continuing or modifying SCIT.

Findings:

• Factors influencing SR risk include asthma control, concomitant medications, pollen exposure, and prior reaction history.
• Treatment adjustments such as dose reduction, altered timing, or switching to sublingual immunotherapy (SLIT) may be considered.
• Anaphylaxis preparedness and pretreatment regimens are vital components of safe SCIT management.

Implications:

• This review provides a framework for clinicians and patients to make informed decisions regarding SCIT continuation or modification after an SR.
• Identifying knowledge gaps emphasizes the need for further research into optimizing SCIT safety and efficacy.
• Personalized risk assessment and management strategies are key to improving outcomes for patients undergoing SCIT.